Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme

Gothenburg, February 12, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, announces today that the company has received notification of a partial payment of EUR 500,000 from the European Innovation Council (EIC) under the framework of its Accelerator Programme. This represents the third payment in a four-part funding program. The remaining grant amount of EUR 375,000 is expected to be disbursed in 2026.

The European Innovation Council's (EIC) Accelerator Programme aims to support innovative small companies through a funding program of up to EUR 2.5 million in grants, along with the possibility of strategic investments. Applications to the program are submitted under highly competitive conditions, with only 5% of applicant companies receiving funding.

EIC awarded Elicera Therapeutics the grant to support the clinical development of its innovative cell therapy, ELC-301. The current EUR 500,000 disbursement has been granted following the company’s reported progress in the ongoing Phase I/IIa clinical study CARMA. The fourth and final payment of EUR 375,000 is expected in 2026.

“We are pleased with the continued funding provided through the European Innovation Council's Accelerator Programme. The capital will be used for the further clinical development of ELC-301 in our ongoing Phase I/IIa CARMA study, where we have recently made promising observations in the treatment of B-cell lymphoma. We look forward to maintaining a strong dialogue with the agency and reporting additional data ahead of the fourth and final payment next year,” says Jamal El-Mosleh, CEO of Elicera Therapeutics.